PMID- 17611570
OWN - NLM
STAT- MEDLINE
DCOM- 20071011
LR  - 20130304
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 21
IP  - 9
DP  - 2007 Sep
TI  - Identification of T-cell epitopes for cancer immunotherapy.
PG  - 1859-74
AB  - The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an 
      optimal immunostimulatory context of the therapy and the proper selection with 
      respect to quality and quantity of the targeted tumor-associated antigens (TAA), 
      and, more precisely, the T-cell epitopes contained in these tumor proteins. Our 
      progressing insight in human leukocyte antigen (HLA) class I and class II antigen 
      processing and presentation mechanisms has improved the prediction by reverse 
      immunology of novel cytotoxic T lymphocyte and T-helper cell epitopes within 
      known antigens. Computer algorithms that in silico predict HLA class I and class 
      II binding, proteasome cleavage patterns and transporter associated with antigen 
      processing translocation are now available to expedite epitope identification. 
      The advent of genomics allows a high-throughput screening for tumor-specific 
      transcripts and mutations, with that identifying novel shared and unique TAA. The 
      increasing power of mass spectrometry and proteomics will lead to the direct 
      identification from the tumor cell surface of numerous novel tumor-specific HLA 
      class I and class II presented ligands. Together, the expanded repertoire of 
      tumor-specific T-cell epitopes will enable more precise immunomonitoring and the 
      development of effective epitope-defined adoptive T-cell transfer and 
      multi-epitope-based vaccination strategies targeting epitopes derived from a 
      wider diversity of TAA presented in a broader array of HLA molecules.
FAU - Kessler, J H
AU  - Kessler JH
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical 
      Center, Leiden, The Netherlands. J.H.Kessler@lumc.nl
FAU - Melief, C J M
AU  - Melief CJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20070705
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
SB  - IM
MH  - Adoptive Transfer/methods
MH  - Cancer Vaccines/immunology
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/*immunology/*therapy
MH  - T-Lymphocytes/*immunology
RF  - 202
EDAT- 2007/07/06 09:00
MHDA- 2007/10/12 09:00
CRDT- 2007/07/06 09:00
PHST- 2007/07/06 09:00 [pubmed]
PHST- 2007/10/12 09:00 [medline]
PHST- 2007/07/06 09:00 [entrez]
AID - 2404787 [pii]
AID - 10.1038/sj.leu.2404787 [doi]
PST - ppublish
SO  - Leukemia. 2007 Sep;21(9):1859-74. doi: 10.1038/sj.leu.2404787. Epub 2007 Jul 5.